Thiery-VuileminAMouilletGTan HonT. Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol. 2014;73:999-1007. doi:10.1007/s00280-014-2435-7.
3.
KovarikJBeyerDSchmouderR.Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Dispos. 2006;27:421-426. doi:10.1002/bdd.524.
4.
PeaFCojuttiPTursiVLiviUBaraldoM.Everolimus overexposure in a heart transplant patient receiving clarithromycin for the treatment of pneumonia. Transpl Infect Dis. 2015;17:926-928. doi:10.1111/tid.12446.
5.
HommaSTakahashiKNiheiSKatoFSugiharaSNunodaS.The successful management of respiratory complications with long-term, low-dose macrolide administration in pediatric heart transplant recipients. Int Heart J. 2014;55:560-563. doi:10.1536/ihj.14-047.
6.
HornJHanstenPChanL.Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41:674-680. doi:10.1345/aph.1H423.
7.
NaranjoCBustoUSellersEM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245. doi:10.1038/clpt.1981.154.